HK1018054A1 - Novel process for the production of amorphous -[r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) - Google Patents

Novel process for the production of amorphous -[r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)

Info

Publication number
HK1018054A1
HK1018054A1 HK98113382A HK98113382A HK1018054A1 HK 1018054 A1 HK1018054 A1 HK 1018054A1 HK 98113382 A HK98113382 A HK 98113382A HK 98113382 A HK98113382 A HK 98113382A HK 1018054 A1 HK1018054 A1 HK 1018054A1
Authority
HK
Hong Kong
Prior art keywords
phenylamino
methylethyl
fluorophenyl
pyrrole
dihydroxy
Prior art date
Application number
HK98113382A
Other languages
English (en)
Inventor
Min Lin
Dieter Schweiss
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1018054(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HK1018054A1 publication Critical patent/HK1018054A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
HK98113382A 1995-07-17 1998-12-15 Novel process for the production of amorphous -[r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) HK1018054A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US145395P 1995-07-17 1995-07-17
PCT/US1996/011807 WO1997003960A1 (en) 1995-07-17 1996-07-16 NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)

Publications (1)

Publication Number Publication Date
HK1018054A1 true HK1018054A1 (en) 1999-12-10

Family

ID=21696097

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98113382A HK1018054A1 (en) 1995-07-17 1998-12-15 Novel process for the production of amorphous -[r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)

Country Status (38)

Country Link
US (1) US6274740B1 (sv)
EP (1) EP0839132B1 (sv)
JP (1) JP4064459B2 (sv)
KR (1) KR100400805B1 (sv)
CN (1) CN1087289C (sv)
AR (1) AR002849A1 (sv)
AT (1) ATE199542T1 (sv)
AU (1) AU700794B2 (sv)
BG (1) BG63631B1 (sv)
BR (1) BR9609714A (sv)
CA (1) CA2220455C (sv)
CO (1) CO4700441A1 (sv)
CZ (1) CZ289421B6 (sv)
DE (1) DE69611999T2 (sv)
DK (1) DK0839132T5 (sv)
EA (1) EA000625B1 (sv)
EE (1) EE03605B1 (sv)
ES (1) ES2156997T3 (sv)
GE (1) GEP20002027B (sv)
GR (1) GR3035859T3 (sv)
HK (1) HK1018054A1 (sv)
HR (1) HRP960312B1 (sv)
HU (1) HU220343B (sv)
IL (1) IL122161A (sv)
IN (1) IN185276B (sv)
MX (1) MX9708959A (sv)
NO (1) NO309322B1 (sv)
NZ (1) NZ313008A (sv)
PE (1) PE1698A1 (sv)
PL (1) PL191017B1 (sv)
PT (1) PT839132E (sv)
RO (1) RO120069B1 (sv)
SI (1) SI0839132T1 (sv)
SK (1) SK283204B6 (sv)
UA (1) UA50743C2 (sv)
UY (1) UY24286A1 (sv)
WO (1) WO1997003960A1 (sv)
ZA (1) ZA966043B (sv)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (sv) 1989-07-21 1995-08-25 Warner Lambert Co Förfarande för framställning av farmaceutiskt användbar /R-(R*,R*)/-2-(4-fluorfenyl)- , -dihydroxi-5-(1-metyletyl)-3-fenyl-4-/(fenylamino)karbonyl/-1H-pyrrol-1-heptansyra och farmaceutiskt användbara salter därav
IN191236B (sv) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US6646133B1 (en) 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
KR100877165B1 (ko) 2000-11-16 2009-01-07 테바 파마슈티컬 인더스트리즈 리미티드 수산화 칼슘을 이용한[Ｒ(Ｒ*,Ｒ*)]-2-(4-플루오로페닐)-β,δ-디하이드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카보닐]-1Ｈ-피롤-1-헵탄산 에스테르의 가수분해
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622697A1 (en) 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (sv) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
BR0210666A (pt) 2001-06-29 2004-10-05 Warner Lambert Co Formas cristalinas do sal de cálcio do ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)c arbonil]-1h-pirrol-1-heptanóico (2:1) (atorvastatina)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
AU2001284385A1 (en) 2001-08-31 2003-03-10 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
CA2479005C (en) 2002-03-18 2012-05-22 Biocon Limited Amorphous atorvastatin calcium or pravastatin sodium hmg-coa reductase inhibitors of desired particle size
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
CA2491051A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
EA013500B1 (ru) * 2003-04-11 2010-06-30 Лек Фармасьютиклз Д.Д. Способ получения аморфной кальциевой соли аторвастатина
WO2004094343A1 (en) 2003-04-22 2004-11-04 Biocon Limited NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF ß-KETOESTERS
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
WO2005026107A1 (en) 2003-09-18 2005-03-24 Biocon Limited Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
CA2666359A1 (en) * 2004-03-17 2005-10-06 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
JP2007536373A (ja) 2004-05-05 2007-12-13 ファイザー・プロダクツ・インク アトルバスタチンの塩形態
JP5000502B2 (ja) * 2004-07-16 2012-08-15 レツク・フアーマシユーテイカルズ・デー・デー アトルバスタチンカルシウムの酸化分解生成物
US7645888B2 (en) 2004-08-27 2010-01-12 Biocon Limited Process for the production of amorphous atorvastatin calcium
EP1793815A4 (en) * 2004-09-30 2010-12-29 Reddys Lab Ltd Dr AMORPHES ATORVASTATINCALCIUM
TW200942516A (en) * 2004-10-18 2009-10-16 Teva Pharma Processes for preparing amorphous atorvastatin hemi-calcium
JP2008517992A (ja) * 2004-10-28 2008-05-29 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アモルファスのアトルバスタチンを形成する方法
EP1814541A4 (en) * 2004-11-22 2009-10-28 Dexcel Pharma Technologies Ltd STABLE ATORVASTATIN FORMULATIONS
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
KR20070116963A (ko) * 2006-03-01 2007-12-11 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미 칼슘 결정형의 제조 방법
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
WO2009007856A2 (en) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (sv) 1989-07-21 1995-08-25 Warner Lambert Co Förfarande för framställning av farmaceutiskt användbar /R-(R*,R*)/-2-(4-fluorfenyl)- , -dihydroxi-5-(1-metyletyl)-3-fenyl-4-/(fenylamino)karbonyl/-1H-pyrrol-1-heptansyra och farmaceutiskt användbara salter därav
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
PT1148049E (pt) 1995-07-17 2005-02-28 Warner Lambert Co Formas cristalinas de hemi-sal de calcio do acido [r-(r*,r*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil)-1h-pirrole-1-heptanoico (atorvastatina)

Also Published As

Publication number Publication date
CZ289421B6 (cs) 2002-01-16
PL191017B1 (pl) 2006-03-31
CN1190956A (zh) 1998-08-19
BG63631B1 (bg) 2002-07-31
WO1997003960A1 (en) 1997-02-06
PL324463A1 (en) 1998-05-25
EE9700369A (et) 1998-06-15
HU220343B (hu) 2001-12-28
DE69611999D1 (de) 2001-04-12
KR19990029045A (ko) 1999-04-15
IL122161A0 (en) 1998-04-05
HUP9903017A3 (en) 2001-01-29
IN185276B (sv) 2000-12-16
HRP960312A2 (en) 1998-02-28
AU700794B2 (en) 1999-01-14
US6274740B1 (en) 2001-08-14
SI0839132T1 (sv) 2001-06-30
ATE199542T1 (de) 2001-03-15
CZ12298A3 (cs) 1998-12-16
NO980209D0 (no) 1998-01-16
EE03605B1 (et) 2002-02-15
EA199800128A1 (ru) 1998-08-27
RO120069B1 (ro) 2005-08-30
DK0839132T3 (da) 2001-04-09
GEP20002027B (en) 2000-04-10
AR002849A1 (es) 1998-04-29
UY24286A1 (es) 1997-01-17
CA2220455A1 (en) 1997-02-06
KR100400805B1 (ko) 2003-12-24
DE69611999T2 (de) 2001-07-26
BG102188A (en) 1998-08-31
MX9708959A (es) 1998-03-31
HRP960312B1 (en) 2001-10-31
CN1087289C (zh) 2002-07-10
SK5898A3 (en) 1998-08-05
CA2220455C (en) 2002-09-24
ZA966043B (en) 1997-02-03
ES2156997T3 (es) 2001-08-01
GR3035859T3 (en) 2001-08-31
JPH11510486A (ja) 1999-09-14
BR9609714A (pt) 1999-02-23
NO309322B1 (no) 2001-01-15
UA50743C2 (uk) 2002-11-15
EP0839132B1 (en) 2001-03-07
CO4700441A1 (es) 1998-12-29
PE1698A1 (es) 1998-02-19
DK0839132T5 (da) 2006-03-20
EP0839132A1 (en) 1998-05-06
IL122161A (en) 1999-07-14
AU6497896A (en) 1997-02-18
EA000625B1 (ru) 1999-12-29
JP4064459B2 (ja) 2008-03-19
NO980209L (no) 1998-01-16
NZ313008A (en) 2000-01-28
PT839132E (pt) 2001-06-29
SK283204B6 (sk) 2003-03-04

Similar Documents

Publication Publication Date Title
HK1018054A1 (en) Novel process for the production of amorphous -[r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HK1018052A1 (en) Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
IL158790A0 (en) Crystalline forms of [r-(*,r*)]-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
ZA966045B (en) Form III crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-B,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1).
DE69616358D1 (de) Kristalline form iii des hemi calcium salzes von [r-(r*,r*)]-2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin)
NZ507836A (en) Crystalline [r*(r* ,r*)]-2-(4-flurophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20160715